300583 赛托生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.716-4.062-4.6102.4442.467
总资产报酬率 ROA (%)1.023-2.446-2.8331.4631.407
投入资产回报率 ROIC (%)1.137-2.689-3.1311.6621.651

边际利润分析
销售毛利率 (%)25.43215.00219.13322.31220.792
营业利润率 (%)6.634-7.500-10.5152.5583.752
息税前利润/营业总收入 (%)9.393-4.420-7.2647.0906.327
净利润/营业总收入 (%)5.053-8.328-10.4403.7933.236

收益指标分析
经营活动净收益/利润总额(%)98.33450.73653.08166.44493.424
价值变动净收益/利润总额(%)8.107-8.106-12.0196.75416.689
营业外收支净额/利润总额(%)-0.2171.0380.66838.783-2.743

偿债能力分析
流动比率 (X)1.2621.2771.2551.4171.051
速动比率 (X)0.8060.8030.6250.6840.490
资产负债率 (%)39.22139.21137.73036.25640.886
带息债务/全部投入资本 (%)32.49333.58231.75028.15032.585
股东权益/带息债务 (%)205.817195.635209.974245.515204.788
股东权益/负债合计 (%)151.992152.050161.094171.277140.442
利息保障倍数 (X)3.386-1.400-2.1872.4352.365

营运能力分析
应收账款周转天数 (天)83.81081.96587.81965.92053.652
存货周转天数 (天)184.277233.688313.608240.947197.357